Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ampligen as an adjuvant to influenza vaccination in healthy older adults
ACTRN12609000083291Phase 2Completed
- Sponsor
- AIM ImmunoTech
- Start
- Mar 2007
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2 trial of rintatolimod and influenza vaccine, sponsored by AIM ImmunoTech. Started Mar 2007; status: completed.
02
Drugs
rintatolimodinfluenza vaccine
Beyond the preview
Go deeper on ACTRN12609000083291.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12609000083291.